Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (451-460 of 545) with videos related to

Pageof 55
Sort By:
Gynecologic Oncology|July 1, 1993
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinomaB Reichman, M Markman, T Hakes, et al.
Gynecologic Oncology|February 1, 1993
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal deliveryM Markman, D Alberts, S Rubin, et al.
Gynecologic Oncology|May 1, 1993
Impact of age on survival of patients with ovarian cancerM Markman, J L Lewis, P Saigo, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapyM Markman, W Jones, J L Lewis, et al.
Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.
Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.
Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Pageof 55

Showing results (451-460 of 545) with videos related to

Sort By:
Pageof 55
Gynecologic Oncology|July 1, 1993
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinomaB Reichman, M Markman, T Hakes, et al.
Gynecologic Oncology|February 1, 1993
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal deliveryM Markman, D Alberts, S Rubin, et al.
Gynecologic Oncology|May 1, 1993
Impact of age on survival of patients with ovarian cancerM Markman, J L Lewis, P Saigo, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapyM Markman, W Jones, J L Lewis, et al.
Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.
Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.
Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Pageof 55